Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis

Osteoarthritis and Cartilage

Volumn 11, Issue 10, 2003, Pages 738-746

  Rudolphi, Karl ^a   Gerwin, N ^a   Verzijl, N ^b   van der Kraan, P ^c   van den Berg, W ^c  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b TNO   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; Histopathology; Interleukin 1 converting enzyme inhibition; Osteoarthritis

Indexed keywords

COLLAGENASE; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; PRALNACASAN; PYRIDINOLINE; RU 36384; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FEMUR CONDYLE; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; JOINT INJURY; KNEE OSTEOARTHRITIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STRUCTURE ANALYSIS; TIBIA; URINALYSIS;

EID: 0141727395     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(03)00153-5     Document Type: Article

References (29)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected-musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778-99.
2. Hough AJ. Pathology of osteoarthritis. In: Moskowitz RW, Howell DS, Altman RD, Buckwalter A Goldberg VM, Eds. Osteoarthritis - Diagnosis and Medical/Surgical Management. Philadelphia: W.B. Saunders Company 2001;69-99.
3. Poole AR, Howell DS. Etiopathogenesis of osteoarthritis. In: Moskowitz RW, Howell DS, Altman RD, Buckwalter JA, Goldberg VM, Eds. Osteoarthritis - Diagnosis and Medical/Surgical Management. Philadelphia: W.B. Saunders Company 2001;29-47.
4. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease. Arthritis Rheum 2001;44:1237-47.
5. van den Berg WB. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Z Rheumatol 1999;58:136-41.
6. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;4:694-703.
7. Saha N, Moldovan F, Tardif G, Pelletier JP, Cloutier JM, Martel-Pelletier J. Interleukin-1β-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1β and interleukin-18. Arthritis Rheum 1999;42:1577-87.
8. Nouri AM, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984;55:295-302.
9. Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, et al. Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother 2002 March-April;1(Suppl 25):S61-4.
10. Kronheim SR, Mimma A, Greenstreet T, Glackin PJ, van Ness K, March CJ, et al. Purification of interleukin-1 beta converting enzyme, the protease that cleaves the interleukin-1 beta precursor. Arch Biochem Biophys 1992;296:698-703.
11. Melchiorri C, Meliconi R, Fizziero L, Silvestri T, Pulsatelli L, Mazzetti I, et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998;41:2165-74.
12. Martel-Pelletier J, McCollum R, Battista A Faure MP, Chin JA, Fournier S, et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biological function. Arthritis Rheum 1992;35:530-40.
13. Chambers MG, Bayliss MT, Mason RM. Chondrocyte cytokine and growth factor expression in murine osteoarthritis. Osteoarthritis Cartilage 1997;5:301-8.
14. Yasuda T, Poole AR. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum 2002;46:138-48.
15. Caron JP, Fernades JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of IL-1 ra in experimental OA. Arthritis Rheum 1996;39:1535-44.
16. Cook JL, Anderson CC, Kreeger JM, Tomlinson JL. Effects of human recombinant interleukin-1beta on canine articular chondrocytes in three-dimensional culture. Am J Vet Res 2000 July;61:766-70.
17. Nietfeld JJ, Wilbrink B, Helle M, van Roy JL, den Otter W, Swaak AJ, et al. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990;33:1695-701.
18. Samad TF, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
19. van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LBA, van den Berg WB. Degenerative knee joint lesions in mice after a single intra-articular collagenase injection. A new model of osteoarthritis. J Exp Pathol 1990;71:19-31.
20. Sokoloff L. Natural history of degenerative joint disease in small laboratory animals. 1. Pathological anatomy of degenerative joint disease in mice. Arch Pathol 1956;62:118-28.
21. Sokoloff L, Jay GE. Natural history of degenerative joint disease in small laboratory animals. 2. Epiphyseal maturation and osteoarthritis of the knee of mice of inbred strains. Arch Pathol 1956;62:129-35.
22. Schünke M, Tillmann B, Bruck M, Müller-Ruchholtz W. Morphologic characteristics of developing osteoarthritic lesions in the knee cartilage of STR/1N mice. Arthritis Rheum 1988;31:898-905.
23. 't Hart BA, Bank RA, de Roos JA, Brok H, Jonker M, Theuns HM, et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol 1998; 37:314-23.
24. Ku G, Ford P, Raybuck SA, Harding MW, Randle JCR. Selective interleukin-1β converting enzyme (ICE/caspase-1) inhibition with pralnacasan (HMR 3480/VX-740) reduces inflammation and joint destruction in murine type ii collagen-induced arthritis (CIA). Arthritis Rheum 2001;44:S241.
25. Verzijl N, Wachsmuth L, TeKoppele JM, Raiss RX. Urinary collagen cross-link excretion in STR/1N mice indicates cartilage destruction as an early event in the development of spontaneous osteoarthritis. Trans Orthop Res Soc 2001;26:271.
26. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
27. Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000; 8:180-5.
28. Otterness IG, Weiner E, Swindell AC, Zimmerer RO, Ionescu M, Poole AR. An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical end-points. Osteoarthritis Cartilage 2001;9:224-31.
29. Pavelka K, Kuba V, Moeller Rasmussen J, Mikkelsen K, Tamasi L, Vitek P, et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient PhII trial in rheumatoid arthritis (RA). Arthritis Rheum 2002;44(Suppl 9):S241.